Japan And Edison
TOKYO, Japan and EDISON, New Jersey, February 3 - Daiichi Sankyo Company, Limited (TSE: 4568), announced today that it has
initiated a new large-scale pivotal Phase III trial for edoxaban, its
investigational oral Factor Xa inhibitor.
